Recent figures indicate that cancer survival rates among Americans have reached unprecedented levels, the result of years of scientific progress, timely screening, and improved therapies.
A new report from the American Cancer Society highlights a remarkable shift in cancer outcomes across the United States. According to the annual report released on January 13, approximately seven in ten patients now survive five years or longer following a cancer diagnosis. This figure represents a dramatic increase from the mid-1970s, when only half of diagnosed individuals reached the same milestone. The data analyzed covers diagnoses between 2015 and 2021, and the five-year survival benchmark remains a standard measurement for assessing progress against the disease.
The report also underscores a continued decline in cancer mortality rates through 2023, estimating that nearly 4.8 million deaths have been prevented since 1991. Researchers attribute this decline to reductions in smoking, earlier and more precise detection, and improvements in treatment strategies. Rebecca Siegel, lead author of the report and senior scientific director of surveillance research at the American Cancer Society, emphasized that these outcomes reflect the long-term impact of sustained cancer research efforts. She described the progress as a transformation of many cancers from once-lethal diagnoses into manageable or chronic conditions.
The influence of genetics and the impact of targeted therapies
Advances in understanding the genetic foundations of cancer have significantly contributed to rising survival rates. Dr. Leonard Kalman, executive deputy director and chief medical officer at Miami Cancer Institute, explains that pinpointing precise genetic mutations within tumors enables physicians to employ precision medicine strategies. “Once a mutation is detected, it can frequently be paired with a targeted therapy that may either cure patients or prolong remission,” Kalman noted. This individualized method is transforming once‑fatal cancers into conditions that can be managed effectively over time, enhancing both life expectancy and overall quality of life for many individuals.
Targeted treatments are increasingly common for cancers such as breast, colorectal, and lung cancers, where molecular profiling guides therapy decisions. Researchers are also expanding the use of immunotherapy, which harnesses the body’s immune system to fight cancer cells, and combination therapies, which pair traditional chemotherapy or radiation with newer drugs. These strategies, combined with early detection through screening programs, have contributed to the substantial gains in survival documented in the report.
Notable improvements in survival for high-mortality cancers
Although overall survival gains are substantial, the most dramatic progress has emerged in cancers once linked to very low survival prospects. Five-year survival for multiple myeloma, a type of bone marrow cancer, has climbed from 32% to 62%. Liver cancer survival has risen from 7% to 22%, and lung cancer rates have advanced from 15% to 28%. These shifts highlight how scientific breakthroughs and public health efforts focused on prevention, timely diagnosis, and effective care have reshaped outcomes.
Despite these positive trends, experts caution that challenges remain. Dr. Sara Myers, a breast cancer surgeon and leader of the BRIDGE program at The Ohio State University Comprehensive Cancer Center, noted that while the results are encouraging, significant disparities persist in access to care and screening. “It’s vital to ensure that patients not only receive effective treatment but also maintain a good quality of life, minimizing severe side effects,” Myers said. She emphasized that equitable access to care and supportive services remains critical for continuing the upward trend in survival.
Ongoing hurdles and inequalities
Cancer continues to be a leading cause of death in the United States, and certain forms remain particularly deadly. Lung cancer is projected to account for the most cancer-related deaths in 2026, surpassing the combined fatalities from colorectal and pancreatic cancers. Additionally, the incidence of common cancers, including breast and prostate cancer, continues to rise, underscoring the need for ongoing prevention and early detection efforts.
Socioeconomic, racial, and ethnic disparities continue to influence outcomes, with underserved populations often experiencing delayed diagnoses and limited access to advanced treatments. Funding for cancer research, traditionally supported by the federal government, has faced reductions that threaten the sustainability of ongoing studies and the development of new therapies. Shane Jacobson, CEO of the American Cancer Society, warned that setbacks in research funding and health insurance access could undermine progress and slow future breakthroughs.
Dr. Kalman expressed similar worries about potential funding reductions, emphasizing that decades of dedicated investment are only now delivering measurable improvements in patient survival. He noted that “the possibility of undermining this hard-won progress is profoundly troubling.” Ongoing backing for research efforts and fair healthcare policies remains critical to prevent recent survival advances from being lost.
Ongoing advancement and optimism
Although obstacles persist, the broader outlook stays encouraging, as advances in genetic science, targeted treatments, immunotherapy, and strengthened public health initiatives are expected to further enhance cancer outcomes. Growing public understanding of preventive steps, from quitting smoking and maintaining a balanced diet to undergoing routine screenings and receiving vaccines against cancer‑related viruses, also supports sustained long‑term progress.
The report emphasizes that the battle against cancer remains ongoing, noting that sustained research funding, broader availability of advanced therapies, and efforts to reduce inequities are vital for continued advancement. For patients and families impacted by the disease, the trends presented in the American Cancer Society report provide encouragement, showing that survival is becoming more achievable and that cancer is increasingly manageable as a long-term condition.
The new findings reflect decades of dedication by researchers, clinicians, and public health advocates to improve cancer outcomes in the United States. With continued investment, innovation, and equitable healthcare access, survival rates are likely to improve further, offering renewed optimism to patients, families, and healthcare providers nationwide.
